Читать книгу Protocols for High-Risk Pregnancies - Группа авторов - Страница 23

Identifying pregnant women who use tobacco, specifically cigarettes, e‐cigarettes and smokeless tobacco, is critical to the cessation and reduction of morbidity. Ideally, this would be identified prior to the pregnancy, when the risks associated with smoking in pregnancy could be discussed and the benefits of smoking cessation emphasized. Screening at prenatal visits using biochemical markers of tobacco exposure may have some utility in identification and cessation of tobacco use. Cotinine, a metabolite of nicotine, is an accurate assay for nicotine exposure when measured in urine and can be part of a cost‐effective cessation program. Studies indicate higher success rates when participants are aware that compliance is measured with biochemical tests. However, this has not been accepted into routine clinical practice at this time.